Novartis delivers strong performance in first half of 2007 (H1 - Report)

Commenting on the results, Dr. Daniel Vasella, Chairman and CEO of Novartis said: "All areas of our strategic healthcare portfolio performed well in the first half of 2007 despite some setbacks in the Pharmaceuticals Division. Continuing our focus on innovation, we have already achieved seven major regulatory approvals this year and more are expected in the second half. Many of these new products are meeting high expectations, while our leading brands Diovan and Gleevec/Glivec keep growing dynamically. Sandoz and Vaccines and Diagnostics again delivered strong growth. Our complementary healthcare businesses are positioning us well to fulfill a broad spectrum of patient needs and meet the...

Want to see the full article?

• Purchase this article for only $3.00